A medication now in its fifth year of clinical use works by targeting a single altered enzyme present in some patients with acute myeloid leukemia or bile duct cancer. Ivosidenib, marketed as Tibsovo, functions by blocking a specific biological mechanism.
That mechanism involves the IDH1 enzyme, which, when mutated, causes cells to produce a compound called 2-hydroxyglutarate, or 2-HG. Unlike normal metabolic byproducts, 2-HG is an oncometabolite—a substance that actively promotes cancer growth and prevents healthy cell maturation. Ivosidenib halts this process.
By inhibiting the mutated IDH1, the drug reduces 2-HG levels. Cancer cells, no longer trapped in a state of unchecked proliferation, begin to differentiate.
They shed their malignant characteristics and start to resemble normal cells. This leads to a decrease in the cancerous cell population and, for many patients, an alleviation of disease symptoms. The U.S. Food and Drug Administration approved ivosidenib in July 2018, designating it a first-in-class medication.
This designation indicates that ivosidenib was the initial drug to operate through this specific mechanism—a small molecule inhibitor directed at a mutated IDH1 enzyme. Prior to this approval, physicians treating acute myeloid leukemia or cholangiocarcinoma had fewer therapeutic options that addressed the specific genetic drivers of a patient’s cancer.
This approach reflects the principles of precision oncology. Rather than using broad chemotherapy that affects all dividing cells, the strategy involves identifying the mutation driving a particular cancer and blocking it. Ivosidenib fits this model. Its mechanism is specific; it does not treat all cases of acute myeloid leukemia or cholangiocarcinoma.
Instead, it treats only the subset of these cancers driven by an IDH1 mutation. While this subset is not insignificant, it is distinct, and testing for the mutation is necessary before a patient can receive the drug.
By May 2023, ivosidenib had become a standard option for these patients. The approval process itself reflected changes in oncology. The FDA granted accelerated approval based on early trial data showing that ivosidenib could induce complete remissions in some patients with relapsed or refractory acute myeloid leukemia.
The rationale was that a drug clearly hitting a known target and producing such responses warranted early access. Later confirmatory trials supported that decision.
For cholangiocarcinoma, or bile duct cancer, the drug offered a similar benefit. A subset of these patients carry the IDH1 mutation. Before ivosidenib, they had few effective treatments after standard chemotherapy failed.
The drug provided a targeted option where none previously existed. The story of ivosidenib is not one of a cure.
It is a story of a precise tool. It does not work for everyone. It works for those whose cancer cells carry the specific altered enzyme.
For them, it can mean reduced tumor burden, a return to more normal blood cell counts, and time—time that was not available before the drug existed. This is the context in which the drug sits: years of basic research into cancer cell metabolism, the identification of the IDH1 mutation in multiple tumor types, and the design of a molecule that could fit into the mutated enzyme and shut it down.
The result is a treatment that does not simply poison cells but redirects them. It represents a different kind of attack on cancer, and as of July 2018, it became available to patients in the United States.
